Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
Journey Medical (Nasdaq: DERM) will release first quarter 2026 financial results after U.S. markets close on Wednesday, May 13, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Journey Medical (Nasdaq: DERM) will release first quarter 2026 financial results after U.S. markets close on Wednesday, May 13, 2026.
Management will host a conference call and audio webcast on May 13, 2026 at 4:30 p.m. ET. Domestic dial-in is 1-866-777-2509; international dial-in is 1-412-317-5413. Registration is available at the provided URL and a replay will be available for ~30 days.
Details
News Market Reaction – DERM
On May 7, the first trading day after this news, DERM closed 4.03% below the previous close.
Data tracked by StockTitan Argus for the May 7 session.
Key Figures
- Earnings release date
- May 13, 2026
- Q1 2026 financial results to be released after U.S. market close
- Conference call time
- 4:30 p.m. ET
- Q1 2026 results conference call and webcast
- U.S. dial-in
- 1-866-777-2509
- Domestic participants access number for Q1 2026 call
- International dial-in
- 1-412-317-5413
- International participants access number for Q1 2026 call
- Replay duration
- 30 days
- Webcast replay available on company website after the call
Previous Earnings date Reports
-
Scheduled release and call for year-end 2025 financial results.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
u.s. food and drug administration regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET
SCOTTSDALE, Ariz., May 06, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2026 financial results after the U.S. financial markets close on Wednesday, May 13, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, May 13, 2026 at 4:30 p.m. ET.
To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call. Participants can register for the conference by navigating to https://dpregister.com/sreg/10209171/10401b25258. Please note that registered participants will receive their dial-in number upon registration.
A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, and will remain available for replay for approximately 30 days after the conference call.
About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.
Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
ir@jmcderm.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.